Page 15 - norgine-annual-report-2016

Priority 3:

Be a dynamic place to work

LYMPHOSEEK is a radiopharmaceutical used for diagnostic purposes
®
of identifying sentinel lymph nodes in adult patients with breast cancer,
melanoma, or localised squamous cell carcinoma of the oral cavity.

It is specifically designed for a procedure called Sentinel Lymph Node
Biopsy (SNB). When injected into a tumour site, LYMPHOSEEK is
®
designed to rapidly pass through the lymphatic system, target and bind to Norgine employs over 1,000 staff, including
the sentinel lymph nodes that drain from that primary tumour and which 470 in commercial activities, and 160 in
have the highest probability of harbouring cancer cells. These sentinel development, medical and regulatory.
lymph nodes can then be removed and examined for cancer by pathology
laboratories, giving essential information to guide future treatment. Being a dynamic place to work is a strategic
priority for Norgine.
In September 2016, The European Medicines Agency approved
a new LYMPHOSEEK 50 microgram kit dosing for European Dynamism, flexibility and teamwork are
®
radiopharmaceutical preparation. at the heart of what Norgine does. That’s
what makes Norgine different. Norgine
Recent data showed that LYMPHOSEEK is highly predictive in the offers employees the flexibility to try new
®
neck of patients with early oral cancer who had no clinical lymph node challenges and give them the opportunity
involvement. If elective neck dissection had been used without sentinel to enhance their skills through targeted
lymph node biopsy, a cancer positive contralateral node may have been development programmes.
missed in 7.2% of the studied patients. In a small number of cases this
was the only cancer positive lymph node. Norgine prides itself in valuing its employees
at all levels by ensuring everyone has a clear
Head and neck cancer is the seventh most common type of cancer role and the tools to be successful
in Europe, with more than 150,000 new patients diagnosed in and contribute to the company’s success.
Europe in 2012. 9 Norgine promotes an environment based on
trust, self-confidence and achievement.
9. http://makesensecampaign.eu/en/cancer-
information/head-neck-cancer/ accessed
on 14 th March 2017 The One Norgine approach enables Norgine
to promote its people internally while still
recruiting external talents. This means that
Norgine has the right professional skills
required in the pharmaceutical and medical
device environment.

Norgine believes that all of its employees
contribute to its future success.

13 14